Justice

November Lawsuit Updates: GLP-1 Warnings, Social Media Deals and a Roundup Verdict

The FDA has ordered vision-risk warnings for all GLP-1 drugs, a development that could support claims in hundreds of Ozempic lawsuits. Other major litigation updates this month include settlements that halted a social media addiction trial and a Roundup verdict favoring Bayer as its proposed $7.25 billion settlement awaits approval.

lake-uankxtpl20t15euqi6743503-eb1fecab-9fa0-4def-98fd-6d928a51d58c-0.webp

FDA requires GLP-1 labels to warn about NAION

On Nov. 9, the U.S. Food and Drug Administration announced that all GLP-1 drug labels must warn about a potentially increased risk of non-arteritic anterior ischemic optic neuropathy, or NAION. This very rare condition involves reduced blood flow to the optic nerve and can leave patients with sudden, permanent vision loss.

The requirement followed the FDA's review of 126 randomized, controlled clinical trials involving multiple types of GLP-1 medications, according to the Association of Optometrists. Researchers found 6.4 NAION cases per 100,000 person-years among patients receiving GLP-1 drugs, versus 3.8 per 100,000 person-years in a comparison group that did not receive them.

Hundreds of people have already filed Ozempic lawsuits alleging that they developed NAION and that manufacturers should have disclosed the risk. The new warning requirement could strengthen that argument, with additional cases continuing to be filed.

Teen settlements halt social media addiction trial

Companies behind Facebook, Instagram and Snapchat reached settlements with two teenagers at the beginning of November, ending a social media addiction trial before opening statements. The teens alleged that the platforms were deliberately designed to addict users and had caused them serious mental health problems.

The agreements are part of a recent pattern of companies settling individual cases as trial dates approach. Bloomberg, in reporting relayed by Yahoo Finance, said Meta agreed to pay two teen plaintiffs a total of $7 million during the two weeks before mid-November. Other recent confidential settlements ranged from $2 million to $2.5 million.

No global agreement has resolved the thousands of remaining individual lawsuits. Bloomberg put the pending personal injury caseload against the four leading social media companies at approximately 9,800 across state and federal courts.

Only one individual case has gone through a completed trial so far. In that case, Meta and YouTube were ordered to pay a combined $6 million to a woman who alleged that using their platforms from a young age had led to severe mental health problems.

Meta has also faced proceedings involving broader claims about children's safety. A New Mexico jury assessed a $375 million penalty in March 2026 after finding that the company's platforms put profits ahead of user safety and harmed children's mental health. In August, Meta agreed to a separate $18 billion settlement, payable over 10 years, with a group of states over claims involving teenagers' use of its platforms.

Bayer prevails on Roundup design defect claims

A Missouri jury unanimously ruled for Bayer in the first Roundup case to reach trial after the U.S. Supreme Court's June 2026 decision limiting failure-to-warn claims. The latest case relied instead on allegations of a design defect.

In the earlier Durnell case, the Supreme Court ruled 7-2 for Bayer and overturned a $1.25 million Missouri jury award. The justices held that the Federal Insecticide, Fungicide, and Rodenticide Act, or FIFRA, preempts state-law claims demanding a cancer warning different from, or additional to, the EPA-approved Roundup label. That decision effectively eliminated the failure-to-warn claims central to the litigation.

Reuters reported that Bayer faced claims from approximately 65,000 plaintiffs in U.S. state and federal courts as of mid-2026. They alleged that using Roundup at home or at work caused non-Hodgkin lymphoma or other cancers.

The litigation has cost Bayer more than $10 billion, according to Claims Journal. Bayer's 2025 annual report recorded plaintiff victories in 11 of the 28 Roundup cases tried since 2015.

Roundup settlement remains pending

Alongside its courtroom defense, Bayer is seeking approval of a $7.25 billion class settlement that could resolve much of the Roundup litigation. Its CEO recently said he expected the agreement to be finalized before Christmas.

Announced in February 2026, the agreement received preliminary approval from a Missouri state court in March. Class members had a June 4 deadline to object or opt out, and the final approval hearing was scheduled for Sept. 14. Bayer did not use its right to terminate the agreement because of the number of opt-outs.

Some law firms representing plaintiffs have criticized the proposed compensation as insufficient for the tens of thousands of people who allege they developed cancer after using Roundup.

Under the proposal, people who have already sued could receive as much as $160,000 each, depending on their age and the severity of their illness. Those with less-aggressive forms of non-Hodgkin lymphoma could receive $40,000. Claims Journal reported those figures from a website maintained by the settlement's supporters. The settlement funds would be distributed over 21 years.

Consumer Rights

Share

Twitter/XFacebookLinkedIn

Read also